title: Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
abstract: Twenty-one patients with type II hyperlipidaemia were treated with the nicotinic acid analogue, acipimox (Olbetam; Farmitalia), for 6 months. Total cholesterol decreased by 10% and the high-density lipoprotein: low-density lipoprotein cholesterol ratio increased by 13%. Triglycerides were unaltered. Two patients stopped the drug after developing gastro-intestinal side-effects. Acipimox therapy warrants ongoing use and further investigation.
authors.affiliation: Institute for Aviation Medicine, Verwoerdburg.
authors.forename: C W
authors.initials: CW
authors.lastname: Barlow
authors.forename: E R
authors.initials: ER
authors.lastname: Soicher
authors.forename: D
authors.initials: D
authors.lastname: Jankelow
authors.forename: D P
authors.initials: DP
authors.lastname: Myburgh
mesh_terms: D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D011719:Pyrazines; D002784:Cholesterol; C027696:acipimox